Alnylam Pharmaceuticals And Two More Value Stocks On US Exchange Estimated To Be Trading Below Intrinsic Value
Yahoo Finance · 1 day ago
Search results
Learn about Alnylam Pharmaceuticals, RNAi therapeutics, and the company's efforts in treating amyloidosis, hyperoxaluria, and porphyria.
- 258.20Add to watchlist+0.43 (+0.17%)As of Thu. Jul 11, 2024 11:24 AM EDT · Nasdaq Real Time Price (USD) · Market open
- Open258.12High260.00Low257.03
- Mkt Cap32.66BP/E (TTM)N/ADiv & YieldN/A & N/A
- Prev. Close257.7652 Wk. Low141.9852 Wk. High260.00
What analysts are sayingTop storiesRelated stocks
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Get the latest Alnylam Pharmaceuticals, Inc. (ALNY) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment...
Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them.
RNAi therapeutics represent an innovative, clinically validated approach to gene silencing. Our multiple approved medicines, and deep pipeline of investigational therapies, are focused on addressing the needs of patients who have limited or inadequate treatment options.
Find the latest Alnylam Pharmaceuticals, Inc. (ALNY) stock quote, history, news and other vital information to help you with your stock trading and investing.
3 days ago · Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference.
View the latest Alnylam Pharmaceuticals Inc. (ALNY) stock price, news, historical charts, analyst ratings and financial information from WSJ.
Jun 24, 2024 · Alnylam is executing on its “Alnylam P 5 x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile.
Jun 24, 2024 · Alnylam said Monday that vutrisiran, an experimental drug for treating a rare condition called transthyretin amyloid cardiomyopathy (ATTR-CM), reduced deaths by all causes and heart-related...
